pharma · Muscle-invasive bladder cancer (MIBC) · Acute ischaemic stroke due to basilar artery occlusion.
Tour Hekla
Tour Hekla is a pharma organization headquartered in EU. Primary therapeutic focus areas include Muscle-invasive bladder cancer (MIBC), Acute ischaemic stroke due to basilar artery occlusion., Thrombotic episodes in supe
Puteaux, Ile de France 92800, FR HQ
6 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Puteaux, Ile de France 92800, FR
- Employees
- 6
- Programs
- 27
- Drugs
- 71
- Patents
- 0
DR200090
Approved · small molecule · Labor Induction of women with an unfavorable Cervix after 24 hours of cervical ripening
DR200090 for Labor Induction of women with an unfavorable Cervix after 24 hours of cervical ripening is a Approved program (small_molecule) at Tour Hekla with 1 ClinicalTrials.gov record(s).
Internal code DR200090
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Tour Hekla
- Phase
- Approved
- Modality
- small_molecule
- Indication
- Labor Induction of women with an unfavorable Cervix after 24 hours of cervical ripening
- Status
- active
- Trials
- 1